Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plA- cebo-controlled, Randomized, double-blINd, 12-week study with an open- label Extension [MARINE] trial). Am J Cardiol. 2011;108:682 690. doi: 222. Christian JB, Arondekar B, Buysman EK, Johnson SL, Seeger JD, Jacobson TA. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceride- mia. J Clin Lipidol. 2012;6:450 461. doi: 10.1016/j.jacl.2012.08.007 223. Rhodes KS, Weintraub M, Marchlewicz EH, Rubenfire M, Brook RD. Medical nutrition therapy is the essential cornerstone for effective treat- ment of refractory severe hypertriglyceridemia regardless of pharmaceu- tical treatment: evidence from a lipid management program. J Clin Lipidol. 224. Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, et al. Effect of high- dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324:2268 2280. doi: 10.1001/jama.2020.22258 225. Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, Nilsen DWT, Tveit A, Fagerland MW, Solheim S, et al; OMEMI Investigators. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarc- tion: a randomized, controlled trial. Circulation. 2021;143:528 539. doi: 226. Brunzell JD, Schrott HG. The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis. Trans Assoc Am Physicians. 1973;86:245 254. 227. 